Therefore, the downregulation of SREBP1 induced by the knockdown of CREB3L2 successfully overcomes lenvatinib resistance in HCC cells via the suppression of lipid metabolism (Fig. 7E). Here, CREB3L2 is linked to hepatocellular carcinoma.